Business
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
DUBLIN, March 09, 2026--Prothena earned a $50 million milestone from Novo Nordisk related to enrollment in the Phase 3 CLEOPATTRA trial evaluating coramitug for ATTR-CM
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3612,"height":1160,"url":"https://media.zenfs.com/en/business-wire.com/4f6b917dda1039a7ff0bd8eab337b307"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hnYna53jxbAldWTU0KohAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4f6b917dda1039a7ff0bd8eab337b307","width":960,"height":308},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/BgvrC4tDrRGORGi055Lmtw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTIwNjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4f6b917dda1039a7ff0bd8eab337b307","width":640,"height":206},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/M5mruVtl1XO2E14VakPZ1Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/4f6b917dda1039a7ff0bd8eab337b307","width":1200,"height":385}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3","length":126,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Prothena has now earned $150 million to date of the $1.2 billion total eligible milestone payments from Novo Nordisk","length":116,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":242,"olType":false},{"type":"text","content":"DUBLIN, March 09, 2026--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company earned a $50 million milestone payment from Novo Nordisk related to the achievement of a prespecified enrollment target in the ongoing Phase 3 CLEOPATTRA clinical trial evaluating coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody, for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).","length":444,"tagName":"p"},{"type":"text","content":"Novo Nordisk is evaluating coramitug in the ongoing Phase 3 CLEOPATTRA clinical trial in approximately 1280 participants with ATTR-CM with primary completion expected in 2029 (NCT07207811).","length":189,"tagName":"p"},{"type":"text","content":"Novo Nordisk gained full worldwide rights to the intellectual property and related rights of the ATTR amyloidosis business and pipeline it acquired from Proth...